Takeda blood disorder drug under USFDA scrutiny after pediatric death
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-11-22 12:57 GMT | Update On 2025-11-22 12:57 GMT
Advertisement
Bengaluru: The U.S. Food and Drug Administration (USFDA) is investigating the death of a child who developed dangerous antibodies after getting Takeda Pharmaceuticals' Adzynma therapy for a rare blood disorder, raising alarm over potential life-threatening outcomes of the drug.
The agency is also evaluating whether additional regulatory action is needed.
"We reported this event to the U.S. Food and Drug Administration and have been providing them with updates since we became aware in July", a
The company has also conducted a thorough assessment and determined that there was no confirmed causal relationship to the use of Adzynma and the patient death, the spokesperson added.
The pediatric patient with cTTP had neurologic symptoms that progressed and developed antibodies that blocked the activity of ADAMTS13. The death occurred about 10 months after starting Takeda's therapy. Before beginning treatment with Adzynma, the patient had previously experienced severe allergic reactions to fresh frozen plasma, which is a traditional treatment for the condition.
The FDA said it has received multiple postmarketing reports of patients developing such antibodies after treatment with Adzynma, though these were not observed during clinical trials.
While the current prescribing information warns about the potential risk of antibody development, it does not include details about postmarketing cases involving serious or fatal outcomes.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.